SCH 50971

Drug Profile

SCH 50971

Latest Information Update: 07 Sep 2001

Price : $50

At a glance

  • Originator Schering-Plough
  • Class Anxiolytics; Gastrokinetics
  • Mechanism of Action Histamine H3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anxiety disorders; Gastrointestinal disorders; Migraine

Most Recent Events

  • 07 Sep 2001 No-Development-Reported for Gastrointestinal disorders in USA (Unknown route)
  • 07 Sep 2001 No-Development-Reported for Migraine in USA (Unknown route)
  • 07 Sep 2001 No-Development-Reported for Anxiety disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top